MRNA

COVID Darling Needs New Tricks

Biotech giant Moderna exploded to the forefront of investors’ minds during the COVID-19 pandemic, playing a pivotal role in bringing the mRNA vaccine to life so quickly. 💉

Its role in the pandemic helped propel its market capitalization from under $10 billion in 2019 to nearly $200 billion at its peak. But as the U.S. and other countries moved past the pandemic’s peak and into a more normalized environment, it’s struggled to maintain that valuation.

Read It

More to Read